• ABOUT
• SERVICES
• PLATFORM
• CLIENT CENTER
• NEWS
• INVESTORS
• CAREERS

|

• ABOUT
• SERVICES
• PLATFORM
• CLIENT CENTER
• NEWS
• INVESTORS
• CAREERS

|

• ABOUT

  Company Profile Management Team Message from the CEO Corporate Culture Company History Honors and Awards

  Over 18 years of experience in R&D Learn more

  

  
• • 01Drug Discovery Chemistry Research Medicinal Chemistry Synthetic Chemistry Analytical Chemistry Biology Research Structural Biology Cell Biology Computational Biology & Molecular Modeling Enzymology & Molecular Interactions Early Pharmacokinetics
  • 02Pharmaceutical Research Intermediates APIs Route Selection Production Process Optimization Clinical Sample Production Impurity Traceability & Control Generic Drug Process Study & Filing Innovative Drug Process Study & Filing Pharmaceutic Preparation Preformulation Study Formulation Technology Research Preparation Quality Research Laboratory-scale Preparation Testing Pilot-scale Preparation Testing GMP-based Clinical Sample Production & Packaging Formulation Stability Study Consistency Evaluation Analytical Method Development & Quality Control CMC Filings
  • 03Preclinical Research Pharmacology & Pharmacodynamics Tumor Models Digestive System Disease Models Endocrine & Metabolic Disease Models Inflammatory & Immune Diseases Models Neural System Disease Models Other Disease Models Drug Safety Evaluation Pharmacology & Toxicology Study Safety Pharmacology Histopathological Study Clinicopathological Study Drug Safety Evaluation Basic Information Toxicokinetics
  •   Pharmacokinetics In Vitro Pharmacokinetic Assays In Vivo Pharmacokinetic Assays Bioanalysis Macromolecular Drugs Bioanalysis Micromolecular Drugs Bioanalysis IND Filings
• • 01One-stop Integrated Services Pharmaceutical Research CDMO Service Platform Chemical Drug Development Medicilon's CDMO Service Platform Preclinical Research Services 02Key Technical Services for Drug R&D Process Department Solid Form Screening Platform SEND Format Conversion Platform Medicilon Flow Cytometry Technology Platform Safety Assessment Lab of Process Chemistry Drug Forming Research Platform MetID Service Platform Cytokine and Biomarker Detection Platform 03Innovative Drug SERVICES Non-clinical Research for Cellular Immunotherapies mRNA Vaccine Bioanalysis Platform PROTAC Drug Discovery Research Platform Antibody-Drug Conjugate(ADC)
  • 04Drug Efficacy Evaluation for Common Diseases Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases IO Pharmacodynamic Model Evaluation Platform 05Advanced Preparation R&D Skin Topical Preparation R&D Ophthalmic drug R&D platform Inhalation drug R&D platform 06Drug Analysis 07Public Services
  Video of Medicilon's Pharmaceutical Research
  
• CLIENT CENTER

  Intellectual Property Protection Downloads Partnerships Newsletters

  Global

  U.S.

  Address: 1 Broadway, Cambridge, MA02142 (America)

  Tel: +1(626)986-9880

   

  UK

  Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

  Tel: 0044 7790 816 954

  Email: marketing@medicilon.com

  China

  Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

  Postcode: 201299

  Tel: +86 (21) 5859-1500 (main line)

  Fax: +86 (21) 5859-6369

• News

  Medicilon Events Featured Stories Market Events Videos

  

  2022-05-07 Featured Stories

  New Drug Discovery and Development

  Drug Discovery Period >> Drug Development and Registration Period >> Drug Release to Market Drug Marketing and Product Line Expansion

  Learn more

  

  2022-05-07 Featured Stories

  Overview of the Drug Discovery Process

  The steps of drug discovery can be simply summarized as disease→target→hit→lead→candidate→drug.

  Learn more
• INVESTORS

  Stock Information Investment Contact

  Medicilon

  688202

  380.17

  RMB

  + 6.37 （ + 1.70 %）

  As of

  2022-05-22 18:26

  Beijing time

  The data is from a third-party organization and is only for reference.

  For actual information, please refer to：www.eastmoney.com
• CAREERS

  Talent Development Employee Activities Campus Recruitment Social Recruitment

  

  Campus Recruitment

  

  Campus Recruitment

  

  Social Recruitment

  

  Social Recruitment

© 2022 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888|Website Map

Close

• ABOUT

  Company Profile Management Team Honors and Awards Corporate Culture

  SERVICES

  Drug Discovery Pharmaceutical Research Preclinical Research

  PLATFORM

  One-stop Integrated Services Key Technical Services for Drug R&D Innovative Drug R&D Services Drug Efficacy Evaluation for Common Diseases Advanced Preparation R&D

  CLIENT CENTER

  Intellectual Property Protection Downloads Partnerships Newsletters

  NEWS

  Medicilon Events Featured Stories Market Events Videos

  INVESTORS

  Stock Information Investment Contact

  CAREERS

  Talent Development Employee Activities Campus Recruitment Social Recruitment

© 2022 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888|Website Map

Close

CN

• Business Inquiry

  Global：

  Email:marketing@medicilon.com

  +1(626)986-9880(U.S. - West Coast)

  0044 7790 816 954 (Europe)

   

  China：

  Email: marketing@medicilon.com.cn

  Tel: +86 (21) 5859-1500

Online Message×

News and Events

News and Events

• 2022-05-05 ·Medicilon Events

  Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use

  Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.

  More
  2022-04-27 ·Medicilon Events

  Medicilon was selected into the "Biomedicine Index"

  Shanghai Medicilon Inc. (Medicilon) was selected as a sample of the Biomedicine Index and became one of the top 5 heavyweight stocks.

  More
  2022-04-27 ·Medicilon Events

  Medicilon was selected as a constituent stocks of the STAR 50 Index

  On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.

  More

2022-05-18 ·Medicilon Events
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology, Pharmacodynamics and Biology Department.
More
2022-05-05 ·Medicilon Events
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.
More
2022-05-05 ·Medicilon Events
Lockdown Never Stopped; Resumption of Work Increases Efficiency
On the evening of March 27, right before the lockdown, Medicilon immediately launched the emergency plan in order to maintain the regular R&D work.
More
2022-04-27 ·Medicilon Events
Medicilon was selected into the "Biomedicine Index"
Shanghai Medicilon Inc. (Medicilon) was selected as a sample of the Biomedicine Index and became one of the top 5 heavyweight stocks.
More
2022-04-27 ·Medicilon Events
Medicilon was awarded the "Top Ten Drug Innovation Service Organizations of the Year" in the 2021 Drug Innovation Award
On April 20th, the 2021 Drug Innovation Award sponsored by Securities Times, Medicilon was awarded the "Top Ten Drug Innovation Service Organizations of the Year" in the 2021 Drug Innovation Award.
More
2022-04-27 ·Medicilon Events
Medicilon was selected as a constituent stocks of the STAR 50 Index
On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.
More
2022-04-27 ·Medicilon Events
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
On March 9, the "Hi Liquid Workplace" 2021 China Annual Best Employer Awards Ceremony of the Yangtze River Delta region ended successfully online. Shanghai Medicilon Inc. (Medicilon) won the "Top 50 China Best Employer Award 2021."
More
2022-04-19 ·Medicilon Events
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Shanghai Medicilon Inc. announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon.
More
2022-04-19 ·Medicilon Events
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Medicilon is deeply aware of its responsibilities toemployees, pharmaceutical companies and scientific research institutions, and even for the entire biopharmaceutical industry chain as an integrated prclinial R&D facility.
More

Featured Stories

More

New Drug Discovery and Development

2022-05-07

More

Overview of the Drug Discovery Process

2022-05-07

More

Stability Studies of Pharmaceuticals

2022-02-09

More

More

Video

More

Drug Discovery

Pharmaceutical Research

Preclinical Research

More

Stock Code

688202

380.17

PM 18:26•2022-05-22

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

© 2022 Shanghai Medicilon Inc. All rights reserved | All Rights Reserved Privacy Policy

Website Map

bioanalytical testing IND Filing PROTAC API ADME Drug Discovery Animal Models Oral Solid Dosage PDX model Pharmacokinetics More